Literature DB >> 22064391

First drugs found to inhibit elusive cancer target.

Melinda Wenner Moyer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22064391     DOI： 10.1038/nm1111-1325

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  Targeting MYC dependence in cancer by inhibiting BET bromodomains.

Authors:  Jennifer A Mertz; Andrew R Conery; Barbara M Bryant; Peter Sandy; Srividya Balasubramanian; Deanna A Mele; Louise Bergeron; Robert J Sims
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

2.  BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authors:  Jake E Delmore; Ghayas C Issa; Madeleine E Lemieux; Peter B Rahl; Junwei Shi; Hannah M Jacobs; Efstathios Kastritis; Timothy Gilpatrick; Ronald M Paranal; Jun Qi; Marta Chesi; Anna C Schinzel; Michael R McKeown; Timothy P Heffernan; Christopher R Vakoc; P Leif Bergsagel; Irene M Ghobrial; Paul G Richardson; Richard A Young; William C Hahn; Kenneth C Anderson; Andrew L Kung; James E Bradner; Constantine S Mitsiades
Journal:  Cell       Date:  2011-09-01       Impact factor: 41.582

3.  c-Myc regulates transcriptional pause release.

Authors:  Peter B Rahl; Charles Y Lin; Amy C Seila; Ryan A Flynn; Scott McCuine; Christopher B Burge; Phillip A Sharp; Richard A Young
Journal:  Cell       Date:  2010-04-30       Impact factor: 41.582

4.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription.

Authors:  Dwayne A Bisgrove; Tokameh Mahmoudi; Peter Henklein; Eric Verdin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-09       Impact factor: 11.205

5.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

6.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.

Authors:  Johannes Zuber; Junwei Shi; Eric Wang; Amy R Rappaport; Harald Herrmann; Edward A Sison; Daniel Magoon; Jun Qi; Katharina Blatt; Mark Wunderlich; Meredith J Taylor; Christopher Johns; Agustin Chicas; James C Mulloy; Scott C Kogan; Patrick Brown; Peter Valent; James E Bradner; Scott W Lowe; Christopher R Vakoc
Journal:  Nature       Date:  2011-08-03       Impact factor: 49.962

7.  Selective inhibition of BET bromodomains.

Authors:  Panagis Filippakopoulos; Jun Qi; Sarah Picaud; Yao Shen; William B Smith; Oleg Fedorov; Elizabeth M Morse; Tracey Keates; Tyler T Hickman; Ildiko Felletar; Martin Philpott; Shonagh Munro; Michael R McKeown; Yuchuan Wang; Amanda L Christie; Nathan West; Michael J Cameron; Brian Schwartz; Tom D Heightman; Nicholas La Thangue; Christopher A French; Olaf Wiest; Andrew L Kung; Stefan Knapp; James E Bradner
Journal:  Nature       Date:  2010-09-24       Impact factor: 49.962
  7 in total
  9 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

2.  A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4.

Authors:  Bradley M Dickson; Parker W de Waal; Zachary H Ramjan; H Eric Xu; Scott B Rothbart
Journal:  J Chem Phys       Date:  2016-10-21       Impact factor: 3.488

3.  Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Authors:  Jeyran Shahbazi; Christopher J Scarlett; Murray D Norris; Bing Liu; Michelle Haber; Andrew E Tee; Alice Carrier; Andrew V Biankin; Wendy B London; Glenn M Marshall; Richard B Lock; Tao Liu
Journal:  Oncotarget       Date:  2014-06-30

4.  Induction of GNMT by 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside through proteasome-independent MYC downregulation in hepatocellular carcinoma.

Authors:  Rajni Kant; Chia-Hung Yen; Jung-Hsien Hung; Chung-Kuang Lu; Chien-Yi Tung; Pei-Ching Chang; Yueh-Hao Chen; Yu-Chang Tyan; Yi-Ming Arthur Chen
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

5.  Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers.

Authors:  Chuan-Huizi Chen; Nong Yang; Yongchang Zhang; Jiancheng Ding; Wenjuan Zhang; Rong Liu; Wen Liu; Ceshi Chen
Journal:  Int J Biol Sci       Date:  2019-06-10       Impact factor: 6.580

6.  The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion.

Authors:  Anna M Jermakowicz; Matthew J Rybin; Robert K Suter; Jann N Sarkaria; Zane Zeier; Yangbo Feng; Nagi G Ayad
Journal:  Sci Rep       Date:  2021-12-03       Impact factor: 4.379

7.  A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways.

Authors:  Ying Liu; Wenjie Liu; Ziqiang Yu; Yan Zhang; Yinghua Li; Dantao Xie; Gang Xie; Li Fan; Shipeng He
Journal:  Cell Death Dis       Date:  2021-06-26       Impact factor: 8.469

Review 8.  Chromatin-regulating proteins as targets for cancer therapy.

Authors:  Takahiro Oike; Hideaki Ogiwara; Napapat Amornwichet; Takashi Nakano; Takashi Kohno
Journal:  J Radiat Res       Date:  2014-02-11       Impact factor: 2.724

9.  Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo.

Authors:  Valentina Maggisano; Marilena Celano; Rocco Malivindi; Ines Barone; Donato Cosco; Catia Mio; Chiara Mignogna; Salvatore Panza; Giuseppe Damante; Massimo Fresta; Sebastiano Andò; Diego Russo; Stefania Catalano; Stefania Bulotta
Journal:  Cancers (Basel)       Date:  2019-12-30       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.